ACTG A5178: LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 人类免疫缺陷病毒(HIV)感染者常合并感染丙型肝炎病毒(HCV)，这两种感染的合并会导致丙型肝炎病毒感染进展为肝硬变。这是一项多中心、II期、开放标签、双臂、长期(90wk)的聚乙二醇化干扰素(SQ，qw)/利巴韦林(po，qd)试验，对象是接受丙型肝炎病毒治疗的初治患者或未能用标准IFNA清除丙型肝炎病毒的患者，以确定它是否减缓了肝纤维化的进展速度。在服用药物期间，患者将接受静脉穿刺术和肝脏活检。在世界范围内，这是一个严重的问题，导致大量的发病率和死亡率。这将寻求确定这种形式的治疗是否初步奏效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with HIV are often co-infected with Hepatitis C virus (HCV), and the combination of these two infections leads to a worse prognosis for the HCV infection with respect to progression to cirrhosis. This is a multicenter, phase II, open-label, 2-arm, long-term (90 wk) trial of PEG-IFN (SQ qw)/ribavirin (po qd) in patients who are HCV-therapy na¿ve or who have failed to clear HCV with standard IFNa to determine whether it slows the rate of progression of hepatic fibrosis. While taking the drugs patients will undergo venipunctures and liver biopsies. Worldwide this is a significant problem leading to a great deal of morbidity and mortality. This will seek to determine whether this form of therapy works in a preliminary fashion.